Navigation Links
Alzheimer’s disease trial With EVT 101 For Successfully Complete

Alzheimer’s disease is a dreaded disease for the elderly. In the direction of its treatment , the effort of Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") has successfully completed the single ascending dose component // of the Phase I clinical study with EVT 101, a subtype-specific NMDA receptor antagonist Alzheimer's disease.

The study comprised 48 young healthy subjects of whom 36 received EVT 101. These showed that EVT 101 was well absorbed, extremely well tolerated with no significant adverse events and had a good pharmacokinetic profile consistent with once or twice daily oral dosing.

The finding is of great importance as non-selective NMDA antagonists have unfavourable side-effect profile. The EVT 101 has now moved into the multiple ascending dose stage of the Phase I study in both young and elderly volunteers.

EVT 101 is a highly potent and selective antagonist of NR2B subunit containing NMDA receptors.

NMDA receptors are important players in certain pathological disease states such as Alzheimer's disease, Parkinson's disease, neuropathic pain and epilepsy. However, the clinical development of non-selective antagonists has been limited by unfavourable side-effects, such as hallucinations. In the early 1990's it was found that multiple NMDA receptor subtypes exist which contain different NR2(A-D) subunits.

In this direction this trial is stepping stone for success. It would be greatly beneficial in treating patients suffering from Alzheimer’s.


'"/>




Page: 1

Related medicine news :

1. Miracle cure for Alzheimer’s around the corner
2. Vaccine for Alzheimer’s diseas
3. High Cholesterol linked to Alzheimer’s diseas
4. Further support for use of statins in Alzheimer’s disease
5. Catching Alzheimer’s Disease Earl
6. Alzheimer’s Continues to Ris
7. Midlife Brain Activity a Predictor Of Alzheimer’s Diseas
8. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
9. Blood Pressure An Early Warning Sign Of Alzheimer’s Disease
10. Delaying The Progression Of Alzheimer’s Disease
11. Hope For Patient With Alzheimer’s Diseas
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ... March 27, 2017 , ... M&S ... Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon M&S's ... standards and specifications such as ANSI, ISO and proven test methods used in ...
(Date:3/27/2017)... PA (PRWEB) , ... March 27, 2017 , ... ... business simulation -centric training, today announced the launch of a new research ... strategy, having the skills needed to execute that strategy, and the actual success ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer ... stages, is more than 95%. Once the cancer spreads to other organs, bones, or ... find out how to avoid this latter group, tune in to Lifestyle Magazine ...
(Date:3/27/2017)... Texas (PRWEB) , ... March 27, 2017 , ... ... at the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate ... and will be an opportunity for area-residents to celebrate two great years while ...
(Date:3/25/2017)... PA (PRWEB) , ... March 25, 2017 , ... Getting ... as a public relations partner. , All through the year, Garden Media aims ... press releases, working with key influencers and pitching client’s key messages to ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
(Date:3/27/2017)... TEL AVIV, Israel , March 27, 2017 ... focused on oncology and immunology, announced today that AGI-134, an ... recently announced acquisition of Agalimmune Ltd., will be featured at ... Meeting in Washington, DC to ... ...
Breaking Medicine Technology: